amiridine and Parkinson-Disease--Secondary

amiridine has been researched along with Parkinson-Disease--Secondary* in 1 studies

Other Studies

1 other study(ies) available for amiridine and Parkinson-Disease--Secondary

Article	Year
[The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys]. Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 114, Issue:11 Development of behavioral disturbances was investigated during N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (0,2 mg/kg, i/m, at 48 h. intervals, total dose 11.2-13.2 mg/kg) in experiments on two monkeys Macaca rhesus. MPTP induced the complex of symptoms, which are typical for idiopathic Parkinson's disease. Administration of amiridine (0,25-0,4 mg/kg) to MPTP-treated monkeys caused gradual decline of Parkinson syndrome. Mechanisms of action of amiridine are discussed. Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Behavior, Animal; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Macaca mulatta; Male; Parkinson Disease, Secondary; Psychotropic Drugs; Time Factors	1992

Article

Year

[The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys].

Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 114, Issue:11

Development of behavioral disturbances was investigated during N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (0,2 mg/kg, i/m, at 48 h. intervals, total dose 11.2-13.2 mg/kg) in experiments on two monkeys Macaca rhesus. MPTP induced the complex of symptoms, which are typical for idiopathic Parkinson's disease. Administration of amiridine (0,25-0,4 mg/kg) to MPTP-treated monkeys caused gradual decline of Parkinson syndrome. Mechanisms of action of amiridine are discussed.

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aminoquinolines; Animals; Behavior, Animal; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Macaca mulatta; Male; Parkinson Disease, Secondary; Psychotropic Drugs; Time Factors

1992